The aforementioned study compared the risk of developing psoriatic or inflammatory arthritis in psoriasis patients who were treated with tumor necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), or IL-12/23i. This evidence concerns the gene IL17A and psoriasis.